 Miriam Post
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stillbirth | 2 | 2024 | 72 | 1.640 |
Why?
| | Placenta | 10 | 2024 | 750 | 1.580 |
Why?
| | Ovarian Neoplasms | 15 | 2024 | 565 | 1.430 |
Why?
| | Uterine Neoplasms | 6 | 2019 | 109 | 1.170 |
Why?
| | Carcinosarcoma | 5 | 2018 | 21 | 1.110 |
Why?
| | Cystadenocarcinoma, Serous | 7 | 2024 | 77 | 1.080 |
Why?
| | Fetal Death | 1 | 2023 | 55 | 0.850 |
Why?
| | Clinical Competence | 3 | 2022 | 1118 | 0.780 |
Why?
| | Pathologists | 3 | 2017 | 18 | 0.750 |
Why?
| | Endometrial Neoplasms | 6 | 2023 | 201 | 0.710 |
Why?
| | Education, Medical, Continuing | 1 | 2022 | 127 | 0.700 |
Why?
| | Microfilament Proteins | 1 | 2017 | 133 | 0.520 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 13 | 0.460 |
Why?
| | Fetal Growth Retardation | 3 | 2024 | 565 | 0.460 |
Why?
| | Autopsy | 2 | 2024 | 95 | 0.420 |
Why?
| | Lymph Nodes | 4 | 2018 | 491 | 0.420 |
Why?
| | Carrier Proteins | 1 | 2017 | 771 | 0.410 |
Why?
| | Pre-Eclampsia | 2 | 2021 | 190 | 0.400 |
Why?
| | Fetus | 3 | 2024 | 806 | 0.400 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 674 | 0.370 |
Why?
| | Immunohistochemistry | 8 | 2023 | 1738 | 0.370 |
Why?
| | Pathology | 3 | 2017 | 24 | 0.360 |
Why?
| | Female | 54 | 2024 | 73304 | 0.360 |
Why?
| | Pregnancy | 11 | 2024 | 6763 | 0.340 |
Why?
| | Biomarkers, Tumor | 10 | 2024 | 1276 | 0.340 |
Why?
| | Prognosis | 11 | 2024 | 4030 | 0.320 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 80 | 0.320 |
Why?
| | Humans | 61 | 2024 | 137585 | 0.310 |
Why?
| | Osteoblastoma | 1 | 2008 | 2 | 0.310 |
Why?
| | Prolactinoma | 1 | 2008 | 13 | 0.310 |
Why?
| | Skull Base | 1 | 2008 | 53 | 0.300 |
Why?
| | Skull Base Neoplasms | 1 | 2008 | 30 | 0.290 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 57 | 0.290 |
Why?
| | Cytomegalovirus | 1 | 2009 | 157 | 0.280 |
Why?
| | Diagnosis, Differential | 6 | 2024 | 1483 | 0.280 |
Why?
| | Peritoneal Neoplasms | 3 | 2014 | 93 | 0.270 |
Why?
| | Fetal Diseases | 1 | 2009 | 173 | 0.270 |
Why?
| | Lymphatic Vessels | 2 | 2018 | 64 | 0.270 |
Why?
| | Uterus | 3 | 2022 | 215 | 0.270 |
Why?
| | Professionalism | 2 | 2017 | 19 | 0.270 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 192 | 0.270 |
Why?
| | Pituitary Neoplasms | 1 | 2008 | 190 | 0.260 |
Why?
| | Interleukin-6 | 3 | 2024 | 778 | 0.260 |
Why?
| | Gestational Age | 4 | 2024 | 910 | 0.260 |
Why?
| | Receptors, Estrogen | 5 | 2017 | 436 | 0.250 |
Why?
| | Infant, Newborn | 4 | 2024 | 6079 | 0.220 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2009 | 394 | 0.220 |
Why?
| | Tryptophan Oxygenase | 1 | 2024 | 34 | 0.220 |
Why?
| | Chorionic Villi | 1 | 2024 | 25 | 0.220 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2021 | 257 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 1079 | 0.210 |
Why?
| | Education, Medical, Graduate | 4 | 2017 | 486 | 0.210 |
Why?
| | Breast Neoplasms | 4 | 2024 | 2253 | 0.210 |
Why?
| | Umbilical Arteries | 1 | 2024 | 55 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1396 | 0.210 |
Why?
| | Neoplasm Invasiveness | 6 | 2018 | 510 | 0.210 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1910 | 0.200 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.200 |
Why?
| | Middle Aged | 22 | 2024 | 33479 | 0.200 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.200 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 9 | 0.200 |
Why?
| | Cell Line, Tumor | 11 | 2024 | 3412 | 0.200 |
Why?
| | Fallopian Tubes | 1 | 2022 | 31 | 0.200 |
Why?
| | Dendritic Cell Sarcoma, Follicular | 1 | 2022 | 2 | 0.200 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 50 | 0.200 |
Why?
| | Internship and Residency | 3 | 2017 | 1147 | 0.200 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 160 | 0.200 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 317 | 0.200 |
Why?
| | Neoplasm Staging | 5 | 2019 | 1389 | 0.190 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2526 | 0.190 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2021 | 683 | 0.190 |
Why?
| | Specialty Boards | 1 | 2022 | 36 | 0.190 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 115 | 0.190 |
Why?
| | Hysterectomy | 3 | 2022 | 129 | 0.180 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2021 | 10 | 0.180 |
Why?
| | Premature Birth | 2 | 2024 | 333 | 0.180 |
Why?
| | Granulosa Cells | 1 | 2021 | 33 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 77 | 0.180 |
Why?
| | Antigens, CD | 2 | 2015 | 521 | 0.180 |
Why?
| | Certification | 1 | 2022 | 113 | 0.180 |
Why?
| | beta Catenin | 2 | 2023 | 253 | 0.180 |
Why?
| | Ovarian Follicle | 1 | 2021 | 72 | 0.170 |
Why?
| | Ovary | 1 | 2022 | 221 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 249 | 0.170 |
Why?
| | Decidua | 2 | 2012 | 24 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2024 | 279 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 801 | 0.170 |
Why?
| | Adult | 22 | 2024 | 37929 | 0.160 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 179 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 539 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 210 | 0.160 |
Why?
| | Phthalazines | 1 | 2019 | 45 | 0.160 |
Why?
| | Leiomyosarcoma | 1 | 2019 | 28 | 0.160 |
Why?
| | Endometrium | 2 | 2022 | 58 | 0.150 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 105 | 0.150 |
Why?
| | Estrogens | 2 | 2012 | 367 | 0.150 |
Why?
| | Up-Regulation | 1 | 2021 | 843 | 0.150 |
Why?
| | Leiomyoma | 1 | 2019 | 77 | 0.150 |
Why?
| | Diverticulum | 1 | 2018 | 12 | 0.150 |
Why?
| | Uterine Diseases | 1 | 2018 | 15 | 0.150 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2018 | 14 | 0.150 |
Why?
| | Gene Expression Profiling | 4 | 2019 | 1774 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 2129 | 0.140 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 136 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2015 | 940 | 0.140 |
Why?
| | Piperazines | 1 | 2019 | 350 | 0.130 |
Why?
| | Fetal Blood | 2 | 2021 | 327 | 0.130 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2017 | 63 | 0.130 |
Why?
| | Extracellular Matrix | 1 | 2021 | 528 | 0.130 |
Why?
| | Blood Vessels | 1 | 2018 | 187 | 0.130 |
Why?
| | B7-H1 Antigen | 3 | 2024 | 217 | 0.130 |
Why?
| | Retinopathy of Prematurity | 1 | 2018 | 142 | 0.130 |
Why?
| | Neoplasm Grading | 3 | 2024 | 307 | 0.130 |
Why?
| | Cisplatin | 2 | 2015 | 320 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2015 | 2475 | 0.120 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 36 | 0.120 |
Why?
| | Employment | 1 | 2017 | 178 | 0.120 |
Why?
| | Endothelial Cells | 1 | 2021 | 785 | 0.120 |
Why?
| | Receptors, Progesterone | 3 | 2015 | 350 | 0.120 |
Why?
| | Pelvic Neoplasms | 1 | 2015 | 26 | 0.120 |
Why?
| | Keratin-5 | 1 | 2015 | 50 | 0.120 |
Why?
| | Job Satisfaction | 1 | 2017 | 218 | 0.120 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 49 | 0.120 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2015 | 35 | 0.120 |
Why?
| | Aged | 13 | 2024 | 23961 | 0.110 |
Why?
| | Incidental Findings | 1 | 2015 | 87 | 0.110 |
Why?
| | Tuberous Sclerosis | 1 | 2015 | 55 | 0.110 |
Why?
| | Skin Neoplasms | 2 | 2012 | 855 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 161 | 0.110 |
Why?
| | Mutation | 2 | 2023 | 3958 | 0.110 |
Why?
| | Mesothelioma, Cystic | 1 | 2014 | 1 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1317 | 0.110 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2014 | 37 | 0.110 |
Why?
| | Chest Pain | 1 | 2015 | 91 | 0.110 |
Why?
| | Capillaries | 1 | 2015 | 108 | 0.110 |
Why?
| | Chorioamnionitis | 1 | 2014 | 42 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1242 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2024 | 528 | 0.110 |
Why?
| | Carcinoma | 1 | 2016 | 240 | 0.110 |
Why?
| | Fertility Preservation | 1 | 2014 | 49 | 0.110 |
Why?
| | Cough | 1 | 2015 | 122 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2019 | 872 | 0.110 |
Why?
| | Glycoproteins | 1 | 2015 | 342 | 0.110 |
Why?
| | Educational Measurement | 1 | 2016 | 289 | 0.110 |
Why?
| | Accreditation | 1 | 2014 | 83 | 0.110 |
Why?
| | Lymphatic Metastasis | 4 | 2018 | 352 | 0.110 |
Why?
| | Sarcoma | 1 | 2016 | 188 | 0.100 |
Why?
| | Adenomyosis | 1 | 2013 | 4 | 0.100 |
Why?
| | Interleukin-8 | 1 | 2014 | 268 | 0.100 |
Why?
| | Survival Rate | 4 | 2018 | 1972 | 0.100 |
Why?
| | Robotics | 1 | 2014 | 94 | 0.100 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2012 | 6 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 254 | 0.100 |
Why?
| | Infertility | 1 | 2013 | 55 | 0.100 |
Why?
| | Luteinizing Hormone | 1 | 2013 | 185 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 27 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 329 | 0.100 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 61 | 0.100 |
Why?
| | Lectins | 1 | 2012 | 49 | 0.100 |
Why?
| | Menstrual Cycle | 1 | 2013 | 133 | 0.100 |
Why?
| | Neural Stem Cells | 1 | 2014 | 156 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2014 | 372 | 0.100 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 49 | 0.100 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 34 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2024 | 15657 | 0.090 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2011 | 17 | 0.090 |
Why?
| | Cicatrix | 1 | 2012 | 64 | 0.090 |
Why?
| | Endometriosis | 1 | 2012 | 51 | 0.090 |
Why?
| | Lymph Node Excision | 3 | 2018 | 171 | 0.090 |
Why?
| | Apoptosis | 4 | 2015 | 2553 | 0.090 |
Why?
| | DNA Polymerase II | 2 | 2023 | 37 | 0.090 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 35 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 399 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 266 | 0.090 |
Why?
| | Paclitaxel | 1 | 2012 | 230 | 0.090 |
Why?
| | Bridged-Ring Compounds | 1 | 2011 | 14 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 24 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2012 | 170 | 0.090 |
Why?
| | Leptin | 1 | 2012 | 236 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2012 | 202 | 0.090 |
Why?
| | Trophoblastic Neoplasms | 1 | 2010 | 2 | 0.090 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 16 | 0.090 |
Why?
| | Neoplasms, Squamous Cell | 1 | 2010 | 4 | 0.090 |
Why?
| | Cesarean Section | 1 | 2012 | 184 | 0.090 |
Why?
| | Taxoids | 1 | 2011 | 102 | 0.090 |
Why?
| | United States | 4 | 2022 | 14841 | 0.090 |
Why?
| | Skin Diseases | 1 | 2012 | 149 | 0.080 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 252 | 0.080 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2010 | 42 | 0.080 |
Why?
| | Biological Evolution | 1 | 2014 | 474 | 0.080 |
Why?
| | Peptides | 1 | 2015 | 985 | 0.080 |
Why?
| | Inflammation | 2 | 2018 | 2837 | 0.080 |
Why?
| | Biopsy | 3 | 2022 | 1129 | 0.080 |
Why?
| | Genital Neoplasms, Female | 1 | 2010 | 90 | 0.080 |
Why?
| | Africa, Eastern | 1 | 2009 | 12 | 0.080 |
Why?
| | Amniocentesis | 1 | 2009 | 25 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1171 | 0.080 |
Why?
| | Fever of Unknown Origin | 1 | 2009 | 12 | 0.080 |
Why?
| | Mice | 8 | 2024 | 17787 | 0.080 |
Why?
| | Infarction | 1 | 2008 | 10 | 0.070 |
Why?
| | Prolactin | 1 | 2008 | 96 | 0.070 |
Why?
| | Blood Chemical Analysis | 1 | 2008 | 99 | 0.070 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 506 | 0.070 |
Why?
| | Viremia | 1 | 2009 | 138 | 0.070 |
Why?
| | Travel | 1 | 2009 | 130 | 0.070 |
Why?
| | Headache | 1 | 2008 | 147 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 434 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 289 | 0.070 |
Why?
| | Models, Statistical | 1 | 2011 | 669 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 622 | 0.070 |
Why?
| | Animals | 10 | 2024 | 36940 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2009 | 285 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 220 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 5778 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2021 | 3556 | 0.060 |
Why?
| | Macrophages | 2 | 2024 | 1547 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2018 | 389 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 692 | 0.060 |
Why?
| | Survival Analysis | 2 | 2021 | 1325 | 0.060 |
Why?
| | Mice, Nude | 3 | 2012 | 698 | 0.060 |
Why?
| | Disease Progression | 3 | 2019 | 2757 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2024 | 7635 | 0.060 |
Why?
| | Cohort Studies | 3 | 2024 | 5742 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5131 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2009 | 893 | 0.060 |
Why?
| | BRCA2 Protein | 1 | 2024 | 63 | 0.050 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2024 | 50 | 0.050 |
Why?
| | Prospective Studies | 3 | 2023 | 7604 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 49 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2024 | 318 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2024 | 124 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.050 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 20 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 92 | 0.050 |
Why?
| | Tryptophan | 1 | 2024 | 183 | 0.050 |
Why?
| | Brain | 1 | 2014 | 2668 | 0.050 |
Why?
| | Ultrasonography | 2 | 2018 | 759 | 0.050 |
Why?
| | Lung | 1 | 2015 | 4060 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1692 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 29 | 0.050 |
Why?
| | Cervix Uteri | 1 | 2021 | 48 | 0.050 |
Why?
| | Maternal Age | 1 | 2021 | 129 | 0.040 |
Why?
| | Mice, SCID | 2 | 2012 | 367 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 217 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 123 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2013 | 3566 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 664 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 840 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 19 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 794 | 0.040 |
Why?
| | Young Adult | 4 | 2021 | 13209 | 0.040 |
Why?
| | Estradiol | 2 | 2013 | 521 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 68 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 42 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 158 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 465 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 433 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 95 | 0.040 |
Why?
| | Ovarian Cysts | 1 | 2018 | 6 | 0.040 |
Why?
| | Pregnancy, Tubal | 1 | 2018 | 5 | 0.040 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.040 |
Why?
| | Salpingectomy | 1 | 2018 | 13 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2031 | 0.040 |
Why?
| | Fetal Development | 1 | 2021 | 296 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2691 | 0.040 |
Why?
| | Pelvic Pain | 1 | 2018 | 34 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 196 | 0.040 |
Why?
| | Frozen Sections | 1 | 2018 | 26 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 167 | 0.030 |
Why?
| | Abortion, Spontaneous | 1 | 2018 | 105 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1759 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 967 | 0.030 |
Why?
| | Risk Factors | 3 | 2018 | 10388 | 0.030 |
Why?
| | Ifosfamide | 1 | 2016 | 37 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 739 | 0.030 |
Why?
| | Faculty | 1 | 2017 | 147 | 0.030 |
Why?
| | Abortion, Induced | 1 | 2018 | 105 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 19 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 57 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2847 | 0.030 |
Why?
| | Risk | 1 | 2018 | 912 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 422 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 617 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 324 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 971 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 150 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 32 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1946 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 686 | 0.030 |
Why?
| | Histones | 1 | 2019 | 636 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 306 | 0.030 |
Why?
| | Follicular Phase | 1 | 2013 | 39 | 0.030 |
Why?
| | Luteal Phase | 1 | 2013 | 45 | 0.030 |
Why?
| | Hysteroscopy | 1 | 2013 | 12 | 0.030 |
Why?
| | Laparoscopy | 1 | 2018 | 466 | 0.030 |
Why?
| | Primates | 1 | 2014 | 126 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 477 | 0.030 |
Why?
| | Cryopreservation | 1 | 2014 | 100 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2012 | 2833 | 0.030 |
Why?
| | Oocytes | 1 | 2014 | 181 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 2012 | 18 | 0.030 |
Why?
| | Male | 4 | 2017 | 67762 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1710 | 0.020 |
Why?
| | Karyotyping | 1 | 2012 | 104 | 0.020 |
Why?
| | Anoikis | 1 | 2012 | 31 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.020 |
Why?
| | Cell Survival | 1 | 2015 | 1120 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2012 | 127 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 852 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 754 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 202 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 861 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2012 | 189 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 56 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 194 | 0.020 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2011 | 63 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 309 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 144 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2012 | 466 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 601 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2010 | 29 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2010 | 69 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2011 | 98 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 219 | 0.020 |
Why?
| | Transfection | 1 | 2012 | 945 | 0.020 |
Why?
| | Organ Specificity | 1 | 2010 | 305 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4149 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 192 | 0.020 |
Why?
| | Adolescent | 1 | 2008 | 21513 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 636 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 1024 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 767 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 279 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1226 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1062 | 0.020 |
Why?
| | Chronic Disease | 1 | 2012 | 1793 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5472 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 2085 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2012 | 630 | 0.020 |
Why?
| | Infant | 1 | 2018 | 9465 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2828 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 10811 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 5079 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|